Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 5/20 | 0.35 |
| ▸ | JAK2 | O60674 | 4/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389923 | 0.95 | FAAH (0.39) | FAAHIRAK4CETPGRIN2BGPR119 | |
| SCHEMBL386227 | 0.92 | GRIN2B (0.33) | FAAHIRAK4CETPGRIN2BMGLL | |
| SCHEMBL390737 | 0.92 | GRIN2B (0.33) | FAAHIRAK4CETPGRIN2BMGLL | |
| SCHEMBL386226 | 0.92 | GRIN2B (0.33) | FAAHIRAK4CETPGRIN2BMGLL | |
| SCHEMBL388785 | 0.90 | IRAK4 (0.33) | JAK1JAK2FAAHIRAK4CETP | |
| SCHEMBL391645 | 0.89 | TLR9 (0.35) | JAK1JAK2IRAK4GRIN2BGPR119 | |
| SCHEMBL388767 | 0.89 | KCNH2 (0.40) | CETPGRIN2B | |
| SCHEMBL390095 | 0.88 | GPR119 (0.45) | FAAHCETPGPR119 | |
| SCHEMBL391559 | 0.87 | JAK1 (0.35) | JAK1JAK2GRIN2BMGLLGPR119 | |
| SCHEMBL391443 | 0.87 | SMYD3 (0.35) | CETPGRIN2BGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193359-B2 | G-protein coupled receptor agonists | PROSIDION LIMITED (GB) | 2012-06-05 | — | — | US | claimed |
| US-8193359-B2 | G-protein coupled receptor agonists | PROSIDION LIMITED (GB) | 2012-06-05 | — | — | US | disclosed |
| US-8193359-B2 | G-protein coupled receptor agonists | PROSIDION LIMITED (GB) | 2012-06-05 | — | — | US | disclosed |
| US-8193359-B2 | G-protein coupled receptor agonists | PROSIDION LIMITED (GB) | 2012-06-05 | — | — | US | disclosed |
| US-8101626-B2 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2004157-B1 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | ARENA PHARM INC (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-2253311-A2 | Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto | Arena Pharmaceuticals, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7816364-B2 | GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20090270422-A1 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090099227-A1 | G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099227-A1 | G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099227-A1 | G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | GPR119, GLP1R, GPR4 | JAK1 2802/4885JAK2 2150/4885FAAH 2029/4885 |
| US-20090270422-A1 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | GPR119, GLP1R, GPR4 | JAK1 2802/4885JAK2 2150/4885FAAH 2029/4885 |
| US-20090099227-A1 | G-Protein Coupled Receptor Agonists | GPR119, GPR65, GPR84 | JAK1 4096/4885JAK2 3744/4885FAAH 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.